L
Linda Mutter
Researcher at Sunesis Pharmaceuticals
Publications - 4
Citations - 3382
Linda Mutter is an academic researcher from Sunesis Pharmaceuticals. The author has contributed to research in topics: BACE1-AS & Presenilin. The author has an hindex of 4, co-authored 4 publications receiving 3298 citations.
Papers
More filters
Journal ArticleDOI
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.
Dale Schenk,Robin Barbour,Whitney Dunn,Grace Gordon,Henry Grajeda,Teresa Guido,Kang Hu,Jiping Huang,Kelly Johnson-Wood,Karen Khan,Dora Kholodenko,Michael K. Lee,Zhenmei Liao,Ivan Lieberburg,Ruth Motter,Linda Mutter,Ferdie Soriano,George Shopp,Vasquez Nicki J,Christopher Vandevert,Shannan Walker,Mark Wogulis,Ted Yednock,Dora Games,Peter Seubert +24 more
TL;DR: It is reported that immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis, and treatment of the older animals markedly reduced the extent and progression of these AD-like neuropathologies.
Journal ArticleDOI
Orally available and efficacious α4β1/α4β7 integrin inhibitors.
Ying-Zi Xu,Jenifer L. Smith,Christopher M. Semko,Kassandra Inez Rossiter,Juri Y Fukuda,Michael S. Dappen,David A. Quincy,Andrei W. Konradi,Wenxian Mao,Brent Welch,Mark Dreyer,Bhushan Samant,Hongbin Zhang,Judevin Lugar,Zhenmei Liao,Carrol Henschel,Eric Petersen,Christopher Vandevert,Mark Shoemaker,Nancy G. Wehner,Linda Mutter,George Shopp,Michael Krimm,Linda Chen,Brian Wipke,Lilibeth Dofiles,Ian Gallager,John-Michael Sauer,Elizabeth Messersmith,Michael A. Pleiss,Frederique Bard,Ted Yednock +31 more
TL;DR: A series of potent α4β1/α4β7 integrin inhibitors is reported, including an inhibitor 12d with remarkable oral exposure and efficacy in rat models of rheumatoid arthritis and Crohn's disease.
Journal ArticleDOI
Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.
Semko Christopher M,Linda Chen,Darren B. Dressen,Mark Dreyer,Whitney Dunn,Francine S. Farouz,Stephen B. Freedman,Elizabeth J. Holsztynska,Michael Jefferies,Andrei W. Konradi,Anna Liao,Judevin Lugar,Linda Mutter,Michael A. Pleiss,Kevin P. Quinn,Thomas N. Thompson,Thorsett Eugene D,Christopher Vandevert,Ying-Zi Xu,Ted Yednock +19 more
TL;DR: Optimization of substituents at the 2 and 5 positions of the pyrimidine ring gave 14, a very potent VLA-4 inhibitor which is orally active in a sheep asthma model.
Journal ArticleDOI
Arylsulfonamide pyrimidines as VLA-4 antagonists.
Ying-Zi Xu,Andrei W. Konradi,Frederique Bard,Michael S. Dappen,Lilibeth Dofiles,Mark Dreyer,Ian Gallager,Caroline Garrido,Mike Krimm,Zhenmei Liao,Elizabeth Messersmith,Linda Mutter,Michael A. Pleiss,Bhushan Samant,Semko Christopher M,Jennifer S. Smith,Frank Stappenbeck,Brian P. Stupi,Chris Vandervert,Brent Welch,Brian Wipke,Ted Yednock +21 more
TL;DR: A series of (S)-2-(2-(diethylamino)-5-(N-alkyl-N-sulfonamido)pyrimidin-4-ylamino-3-(4-(carbamoyloxy)phenyl)propanoic acid is discovered as orally available VLA-4 antagonists and showed efficacy in multiple in vivo animal models.